Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 14/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5054564 | 0.88 | TBXAS1 (0.47) | TBXAS1GRM8GRM4LMNAPOLB | |
| SCHEMBL5053105 | 0.79 | TBXAS1 (0.46) | TBXAS1 | |
| SCHEMBL5054566 | 0.77 | TBXAS1 (0.49) | TBXAS1 | |
| SCHEMBL5052928 | 0.77 | GGH (0.40) | — | |
| SCHEMBL7651193 | 0.75 | GRM8 (0.47) | TBXAS1GRM8GRM4LMNA | |
| SCHEMBL5051209 | 0.74 | TBXAS1 (0.43) | TBXAS1GRM8GRM4LMNA | |
| SCHEMBL5053484 | 0.73 | HDAC3 (0.44) | POLB | |
| SCHEMBL5054578 | 0.73 | GGH (0.40) | TBXAS1GRM8GRM4 | |
| SCHEMBL5052905 | 0.73 | GRM8 (0.47) | TBXAS1GRM8GRM4 | |
| SCHEMBL5054547 | 0.72 | GGH (0.44) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
| US-6025345-A | NOVEL PHOSPHONATE DERIVATIVES, HYDROXYPHOSPHINYL DERIVATIVES, AND PHOSPHORAMIDATE DERIVATIVES THAT INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY, | GUILFORD PHARMACEUTICALS INC. (US) | 2000-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | TBXAS1 1581/4885GRM8 2890/4885GRM4 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.